Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resource Utilization in Severe Mental Illness (SMI) Before, During and After a Psychosocial Health Promotion Program - a Shift in Resource Utilization Towards Primary Care.

Community mental health journal·2026
Same author

Normalization of Haemostasis in People with Haemophilia A: Expert Consensus on Unmet Needs and a Framework for Advancing Towards Health Equity.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

A Randomised Feasibility Trial of a Service-Coordinated Exercise Intervention in First-Episode Psychosis: Challenges in Implementation and Outcome Assessment.

Early intervention in psychiatry·2026
Same author

The imaginary divide between mental and "physical" health: Dismantling dualism and reductionism to address a monumental mistake in medicine.

JCPP advances·2026
Same author

Is a higher antipsychotic dose required to treat relapse in remitted first episode psychosis? A systematic review and meta-analysis.

Schizophrenia research·2026
Same author

New approaches to clinical research for people with schizophrenia.

The British journal of psychiatry : the journal of mental science·2026

Related Experiment Video

Updated: May 31, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

Proportion and Reasons for Clozapine Discontinuation: A Systematic Review and Meta-Analysis.

Paul McLaughlin1, Róisín McManus2, Oisin Conaty1,3

  • 1UCD Centre for Psychosis Research, School of Medicine, University College Dublin, Dublin, Ireland.

Schizophrenia Bulletin Open
|May 29, 2026
PubMed
Summary

Clozapine discontinuation occurs in 34% of patients with treatment-resistant schizophrenia. Non-adherence and side effects are the primary reasons, impacting treatment outcomes.

Keywords:
adverse effectscessationclozapinepsychosistreatment-refractory

Related Experiment Videos

Last Updated: May 31, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

Area of Science:

  • Psychiatry
  • Pharmacology
  • Epidemiology

Background:

  • Clozapine is a critical treatment for treatment-resistant schizophrenia.
  • Understanding clozapine discontinuation is vital due to limited alternative options.

Purpose of the Study:

  • To determine the prevalence of clozapine discontinuation.
  • To identify the main reasons for clozapine discontinuation in patients with schizophrenia.

Main Methods:

  • Systematic review and proportional meta-analysis of observational studies.
  • Searched PubMed and Scopus databases (1988-2025).
  • Assessed study quality using the National Heart, Lung, and Blood Institute Study Quality Assessment Tool.

Main Results:

  • The pooled proportion of clozapine discontinuation was 34% (95% CI, 29%-40%).
  • Non-adherence accounted for 11% (95% CI, 8%-16%) of discontinuations.
  • Side effects accounted for 11% (95% CI, 8%-13%) and ineffectiveness for 7% (95% CI, 5%-9%).

Conclusions:

  • Non-adherence and side effects are the most frequent reasons for clozapine discontinuation.
  • Addressing these factors can optimize clozapine continuation and patient outcomes.
  • Inconsistent reporting of discontinuation reasons may limit the completeness of findings.